PTPN11 and cancer: Increased activity of the ERK pathway is a major driver of adaptive resistance to SHP2 inhibition in cancer cells, and combining SHP2 inhibitors with ERK inhibitors may prevent the development of drug resistance to MEK inhibitors (7, 10, 72, 73).